Efgartigimod for New-onset Generalized Myasthenia Gravis
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- argenx · Industry
This trial is looking for adults who have recently been diagnosed with generalized myasthenia gravis (gMG). Participants will receive treatment with efgartigimod PH20 SC over a period of about 51 weeks.
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with gMG of MGFA class II, III, or IV.
- I have a positive AChR antibody test.
- I have not been treated for gMG before or have used AChEI.
- I had the first signs of gMG less than 1 year ago.
- I have an MG-ADL score of 5 or more.
You may not be able to join if
- I have gMG diagnosed as MGFA class I or V.
- I had a thymectomy before screening, except for a nonmalignant thymoma.
- I have used any systemic corticosteroid therapy for gMG.
- I have used any nonsteroidal immunosuppressive therapy for gMG.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.
Loading trial locations…